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ScienSafety and Efficacy of CMX001 as Salvage
Therapy for Severe Adenovirus Infections
in Immunocompromised Patients
Diana F. Florescu,1 Steven A. Pergam,2,3 Michael N. Neely,4 Fang Qiu,1 Christine Johnston,2,3
SingSing Way,5 Jane Sande,6 Deborah A. Lewinsohn,7 Judith A. Guzman-Cottrill,7
Michael L. Graham,8 Genovefa Papanicolaou,9 Joanne Kurtzberg,10 Joseph Rigdon,11
Wendy Painter,12 Herve Mommeja-Marin,12 Randall Lanier,12 Maggie Anderson,12
Charles van der Horst11No therapeutic agent has yet been established as the definitive therapy for adenovirus infections. We
describe the clinical experience of 13 immunocompromised patients who received CMX001 (hexadecylox-
ypropyl cidofovir), an orally bioavailable lipid conjugate of cidofovir, for adenovirus disease. We retrospec-
tively analyzed 13 patients with adenovirus disease and viremia treated with CMX001; data were available
for $4 weeks after initiation of CMX001 therapy. Virologic response (VR) was defined as a 99% drop
from baseline or undetectable adenovirus DNA in serum. The median age of the group was 6 years (range,
0.92-66 years). One patient had severe combined immunodeficiency, 1 patient was a small bowel transplant
recipient, and 11 were allogeneic stem cell transplant recipients. Adenovirus disease was diagnosed at a me-
dian of 75 days (range, 15-720 days) after transplantation. All patients received i.v. cidofovir for a median of
21 days (range, 5-90 days) before CMX001 therapy. The median absolute lymphocyte count at CMX001
initiation was 300 cells/mL (range, 7-1500 cells/mL). Eight patients (61.5%) had a $1 log10 drop in viral
load after the first week of therapy. By week 8, 9 patients (69.2%) demonstrated a VR, with a median
time to achieve VR of 7 days (range, 3-35 days). The change in absolute lymphocyte count was inversely
correlated with the change in log10 viral load only at week 6 (r520.74; P5.03). Patients with VR had longer
survival than those without VR (median 196 days versus 54.5 days; P5 .04). No serious adverse events were
attributed to CMX001 during therapy. CMX001 may be a promising therapeutic option for the treatment of
severe adenovirus disease in immunocompromised patients.
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disease that is associated with a high rate of mortality
in immunocompromised patients [1,4,5].
The incidence of adenovirus infections in hemato-
poietic stem cell transplantation (HCT) and solid
organ transplantation recipients is increasing, likely
due to a combination of more potent immunosuppres-
sion, improved diagnostic sensitivity (eg, polymerase
chain reaction [PCR]), systematic screening, and an
increasing pool of high-risk recipients with improved
survival [1,6]. Estimates of the incidence of
adenovirus infection in HCT recipients range from
5% to 47%, with the highest rates reported in the
first 100 days posttransplantation [4,5,7-22]. In solid
organ transplantation recipients, rates of adenovirus
infection vary by the organ transplanted, ranging
from 4% to 10% in pediatric liver transplant
recipients [23] to as high as 57% in small bowel trans-
plant recipients [24-26]. Reported mortality rates in
HCT recipients are up to 70% [4,5,7-22], whereas in
solid organ transplantation recipients, mortality
depends on the type of allograft (ranging from 18%
in kidney recipients to 53% in liver recipients) [6].
No currently licensed drug has been established as
the definitive therapy for adenovirus infections. How-
ever, in most transplantation centers, i.v. cidofovir is
used to treat adenovirus disease, albeit without sup-
portive data from randomized controlled clinical trials.
Cidofovir is a nucleoside phosphonate analogue [27]
with significant adverse effects [28]. CMX001 (hexade-
cyloxypropyl cidofovir), a lipid conjugate of cidofovir,
has good oral bioavailability and achieves higher intra-
cellular levels of active drug compared with cidofovir
[29,30]. In contrast to cidofovir, which is inefficiently
taken up by cells, CMX001 resembles natural lipids
and uses lipid uptake pathways in enterocyte and
target-cell membranes to achieve high intracellular
concentrations [29-31]. Inside target cells, the lipid
side chain of CMX001 is cleaved to yield free
cidofovir that is then converted to the active antiviral
agent, cidofovir-diphosphate, by a 2-step phosphory-
lation process catalyzed by intracellular anabolic
kinases [30]. Cidofovir-diphosphate is a potent inhibi-
tor of viral DNA synthesis. A potential advantage of
CMX001 may be a better safety profile relative to
cidofovir [32,33].
CMX001 is currently in clinical trials. The man-
ufacturer (Chimerix, Inc.) and the U.S. Food and
Drug Administration (FDA) have made CMX001
available for compassionate use through an emer-
gency investigational new drug (EIND) mechanism
for patients with severe dsDNA viral infections [34].
In this report, we describe the clinical experience
with CMX001 in treating immunocompromised pa-
tients with adenovirus disease, focusing on clinical ef-
ficacy and safety.METHODS
We retrospectively analyzed the clinical and elec-
tronic records of all pediatric and adult patients who
were granted FDA EIND approval for CMX001 to
treat adenovirus disease between October 2009 and
April 2010. All patients were immunocompromised,
had life-threatening adenovirus disease, and were
refractory or intolerant to standard cidofovir treat-
ment. Informed consent to use CMX001 was obtained
from the patients or proxy at each site. Local Institu-
tional Review Boards provided approval in accordance
with applicable regulations.
Our goal was to assess viral responses to treatment.
We included only patients with adenovirus disease and
viremia for whom data on adenovirus viral load (VL)
were available for at least 4 weeks after initiation of
CMX001, to quantify the response to CMX001 and
compare it with the response to cidofovir. Patients
with adenovirus disease without posttreatment VL
data and patients with end-organ disease without vire-
mia were excluded from our analysis.
Data collected from patients’ medical records
included age, sex, type of graft and transplantation,
immunocompromised state (conditioning regimen,
graft-versus-host disease [GVHD] prophylaxis, induc-
tion therapy, maintenance immunosuppression), pre-
vious rejection and/or GVHD, sites of adenovirus
infection, absolute lymphocyte count (ALC), adenovi-
rus VL, treatment with cidofovir and CMX001, and
other viral coinfections. Adverse events documented
by local investigators were reviewed, with a special
focus on renal and hematologic side effects. Creatinine
clearance was calculated using the Schwartz formula
for children and theCockroft-Gault formula for adults.
Definitions
Adenovirus disease was defined as symptoms and
signs suggestive of infection with no other attributable
cause combined with histopathological documenta-
tion of adenovirus (eg, immunohistochemical staining,
adenovirus inclusion) and/or adenovirus detection by
culture, antigen test, or nucleic acid test from biopsy
specimens, bronchoalveolar lavage fluid, or cerebro-
spinal fluid [26,35]. Disseminated adenovirus disease
was defined as documented disease in 2 or more
organs [1]. Virologic response (VR) was defined as
achievement of $99% decrease in plasma VL from
baseline or undetectable VL by the end of treatment
or follow-up period. Patients with VRwere considered
responders, and those who did not achieve VR were
considered nonresponders. Common Terminology
Criteria for Adverse Events, version 4.0 was used to
define the adverse events. Primary outcome measure-
ments were the proportion with VR and a 1 log10
drop in VL from baseline to the corresponding time
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outcomes included safety evaluations, with an empha-
sis on renal and hematologic outcomes.
Sample Collection and Analysis
After primary diagnosis, serial serum, stool, and
other bodily fluids were collected once or twice weekly
for adenovirus detection. Quantitative real-time adeno-
virus PCR was performed locally using center-specific
methods to detect common serotypes of human adeno-
virus.All resultswere reported as viral copies/mL; all tis-
sue biopsy specimens were routinely sent for
histopathological examination and viral identification
by immunohistochemical staining, culture, and PCR.
CMX001 Dosing
CMX001 dosing varied in the cohort. The first
group of 4 patients received 1 mg/kg/week. Based on
pharmacokinetic and virology results, and in the absence
of safety concerns, the dosewas adjusted to 2mg/kg/wk,
then to 3 mg/kg/week as the cohort progressed. Ther-
apy was adjusted in frequency from weekly to biweekly
on a case-by-case basis by local investigators, guided
by therapeutic drug levels available from the
manufacturing company when available. All patients
received the drug orally or through a nasogastric tube
while in a fasting state (a minimum of 4 hours predose
and 1 hour postdose). No patient received probenecid.
The dose was not adjusted in patients with renal dys-
function. Patients undergoing dialysis received the
drug after dialysis. Treatment was continued until VR
was achieved or to a maximum of 6 months, at which
time the study drug was discontinued. Patients were
monitored by each center for previously described
cidofovir-related toxicities by assessing weekly safety
laboratory results; medical records were thoroughly
reviewed to ensure detection of all potential side effects.
Any side effects considered associated with CMX001
were reported directly to the FDA throughMedWatch,
as well as to the manufacturer.
Statistical Analysis
VL and ALC were recorded at weeks 0, 1, 2, 4, 6,
and 8 after initiation of CMX001; VL was log10-
transformed before analysis. Changes in log10 VL
and ALC measures were defined as the follow-up
measures minus the baseline values. The primary out-
comes of the study—VR and log10 change in VL
from baseline to week 8—were calculated using
a last-observation-carried-forward approach [36]. Dis-
tributions of log10 VL and ALC levels at various time
points were examined using boxplots, and Wilcoxon’s
signed-rank test was used to compare log10 VL,
ALC, and creatinine clearance at baseline and specific
time points during follow-up. Wilcoxon’s signed rank
test was also used to compare change in log10 VLmeasures under cidofovir treatment and under
CMX001 treatment after the same duration of expo-
sure to both drugs. Spearman’s correlation coefficient
was used to examine the relationship between the
change in log10 VL and the change in ALC at each
time point. Continuous variables were compared be-
tween responder and nonresponder groups using the
nonparametric exact Wilcoxon rank sum test, and cat-
egorical variableswere compared using theFisher exact
test. Overall survival was defined as the time interval
from the initiation of CMX001 to death from any cause
or to last follow-up.Kaplan-Meier survival analysis was
performed to estimate overall survival, and the exact
log-rank test was used to compare overall survival dis-
tributions in the responder and nonresponder groups.RESULTS
Patients
Of the 17 FDA EIND patients who received
CMX001, 13 (8 children and 5 adults) were included
in this analysis. Three patients were excluded because
they died before the first posttreatment VL measure-
ment, and 1 patient was excluded because he did not
have viremia. Among the 13 patients included in the
analysis, 1 patient had severe combined immunodefi-
ciency, 1 patient had received a small bowel transplant,
and 11 patients had undergone HCT. Baseline and
posttransplantation demographic data for this cohort
are presented in Table 1.
In addition to viremia, 6 patients (46%) had dis-
seminated adenovirus disease. For the 12 transplant
recipients (small bowel and hematopoietic cell), the
disease was diagnosed at a median of 75 days (range,
15-720 days) after transplantation. The gastrointesti-
nal tract was the most common site involved, affecting
7 patients (53.8%), followed by the genitourinary tract
(n5 4; 30.8%), respiratory (n5 3; 23.1%), and central
nervous system and bone marrow (each n5 1; 7.69%).
Ten patients (76.9%) developed other viral infections,
including 6 with BK virus, 3 with cytomegalovirus,
2 with respiratory syncytial virus, 2 with Epstein-
Barr virus, and 1 each with herpes simplex virus,
human herpesvirus-6, and parainfluenza.
All patients had received cidofovir previously and
had been switched to CMX001 after a median of
21 days (range, 5-90 days). Median adenovirus log10
VL was 4.72 (range, 2-8.04) at cidofovir initiation
and 5.06 (range, 2-7.81) at CMX001 initiation.
Median ALC at CMX001 initiation was 300 cells/mL
(range, 7-1500 cells/mL), reflecting the severity of
immunosuppression in these patients.
Virologic Efficacy
Using matched therapy time (ie, the number of
weeks on cidofovir matched with the number of weeks
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Figure 1. Change in adenovirus VL between cidofovir and CMX001
treatment. The median change in log10 VL on cidofovir treatment (be-
fore receipt of CMX001) was 0.08 (range,22.14 to 4.66) (P5 .95). The
median change in log10 VL for CMX001 treatment was 22.71 (range,
25.63 to 1.1) (P 5 .001). The median was connected over time.
Table 1. Data for Patients with Disseminated Adenovirus
Treated with CMX001 (n 5 13)
Variable n (%)
Age, years, median (range) 6 (0.92-66)
Pediatric (#18 years), n (%) 8 (62)
Adult (>18 years), n (%) 5 (38)
Male sex, n (%) 5 (38)
Underlying risk factors for adenovirus, n (%)
HCT
AML/ALL 5 (38)
CML/CLL 2 (15)
Aplastic anemia 2 (15)
SCID 1 (7)
Non-Hodgkin lymphoma 1 (7)
Other conditions
Solid organ transplantation* 1 (7)
SCID† 1 (7)
Donor stem cell source, n (%)‡
Cord blood 5 (45)
Peripheral blood stem cells 4 (36)
Bone marrow 2 (18)
Conditioning regimen, n (%)‡
Myeloablative 5 (50)
Nonmyeloablative 5 (50)
Receipt of lymphocyte-depleting agents, n (%)§
Rabbit antithymocyte globulin 4 (31)
Alemtuzumab 3 (23)
GVHD grade, n (%)‡
None 3 (27)
I-II 2 (18)
III-IV 5 (45)
Unknown 1 (9)
AML indicates acute myelogenous leukemia; ALL, acute lymphocytic leu-
kemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic
leukemia; SCID, severe combined immunodeficiency disorder.
Percentages reported might not equal 100% because of rounding.
*Small bowel transplant.
†Underwent HCT 7 weeks after initiation of CMX001.
‡Only for HCTrecipients.
§Agent received during conditioning or for treatment of GVHD, but all
given before development of adenovirus.
734 Biol Blood Marrow Transplant 18:731-738, 2012D. F. Florescu et al.on CMX001), the median change in log10 VL on cido-
fovir treatment before initiation of CMX001 was 0.08
(range, 22.14 to 4.66) (P 5 .95 for difference from 0),
whereas the median change in log10 VL on CMX001
treatment was 22.71 (range, 25.63 to 1.1) (P 5 .001).
There also was a significant difference in the decrease
in median change in log10 VL between cidofovir treat-
ment and CMX001 treatment (22.21; range, 26.9 to
2.15) (P5 .003) (Figure 1).
Nine of the 13 patients (69.2%) achieved a VR at
week 8, with a median time to VR of 7 days (range,
3-35 days). At least a 1 log10 drop in VL was seen in
8 patients (61.5%) at week 1, in 9 patients (69.2%) at
week 2, and in 10 patients (76.9%) at week 4. A statis-
tically significant decrease in the median log10 VL
after initiation of CMX001 therapy was seen at all
time points compared with week 0. The median
change was 21.78 (range, 22.91 to 0.46) at week 1
(P 5 .002), 21.77 (range, 24.65 to 0.36) at week 2
(P 5 .0007), 21.89 (range, 24.65 to 1.42) at week 4
(P 5 .002), 22.6 (range, 25.81 to 1.34) at week 6
(P 5 .006), and 23.06 (range, 27.81 to 21.54) at
week 8 (P 5 .004) (Figure 2).As a possible confounder of the virologic efficacy of
CMX001, the difference in the median ALC value
between week 0 and several time points was assessed as
well. The median change was 240 (range, 2100 to
4100) at week 1 (P 5 .01), 100 (range, 2100 to 5300)
at week 2 (P5 .02), 300 (range,2300 to 5100) at week
4 (P 5 .059), 164.5 (range, 2300 to 4700) at week 6
(P 5 .094), and 577 (range, 2300 to 1300) at week 8
(P5 .094) (Figure 2). The change in ALCwas inversely
correlated with the change in log10 VL only at week 6
(r 5 20.18, P 5 .56 at week 1; r 5 0.39, P 5 .19
at week 2; r 5 20.24, P 5 .44 at week 4; r 5 20.74,
P5 .03 at week 6; and r520.49, P5 .33 at week 8).
Responders versus Nonresponders
There were no statistical differences between the
responders and nonresponders with regard to age,
sex, GVHD, median time to infection, adenovirus
log10 VL at cidofovir or CMX001 initiation, days on
cidofovir treatment, total CMX001 exposure, or
ALC at CMX001 initiation (Table 2). Only a trend to-
ward differences was seen in median adenovirus log10
VL at week 4 after initiation of CMX001 (P 5 .07).
Survival
There were no deaths during the first 4 weeks of
treatment, but 3 patients died during the 8-week
follow-up period. The corresponding 8-week survival
rate was 76.9% (95% CI, 44.2%-92%). The median
overall survival time was 101 days (range, 54-213
days). Only 3 patients (23%) remained alive at the last
follow-up; the median follow-up time for the 3 living
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Viral Load (log10 copies/ml)
Absolute Lymphocyte Count (103 cells)
Figure 2. Change in adenovirus VL (log10) and change in ALC after ini-
tiation of CMX001 to week 8 of therapy. The median was connected
over time. The median change in log10 VL (upper part of the graph)
was 21.78 (range, 22.91 to 0.46) from week 0 to week 1 (P 5 .002),
21.77 (range, 24.65 to 0.36) from week 0 to week 2 (P 5 .0007),
21.89 (range, 24.65 to 1.42) from week 0 to week 4 (P 5 .002),
22.6 (range, 25.81 to 1.34) from week 0 to week 6 (P 5 .006), and
23.06 (range, 27.81 to 21.54) from week 0 to week 8 (P 5 .004).
The median change in ALC (lower part of the graph) was 40 (range,
2100 to 4100) from week 0 to week 1 (P 5 .01), 100 (range, 2100
to 5300) from week 0 to week 2 (P 5 .02), 300 (range, 2300
to 5100) from week 0 to week 4 (P 5 .059), 164.5 (range, 2300 to
4700) from week 0 to week 6 (P 5 .094), and 577 (range, 2300
to 1300) from week 0 to week 8 (P 5 .094).
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with nonresponders, complete responders had longer
survival (median, 196 days versus 54.5 days; P 5 .04)
(Figure 3). The 8-week survival rate after CMX001
treatment was 88.9% (95% CI, 43.3%-98.4%) for
responders and 50% (95% CI, 5.78%-84.5%) for
nonresponders. Adenovirus pneumonia was the cause
of death in 1 patient.Table 2. Comparison of Variables in Responders and Nonresponde
Variable Re
Demographic factors
Age, years, median (range)
Pediatric, n (%)
GVHD, n (%)
Acute renal failure before CMX001 initiation, n (%)
Time to infection after HCT, days, median (range)
Pretreatment factors
Days on cidofovir before CMX001 initiation, median (range)
Adenovirus, log10 VL at cidofovir initiation, median (range)
Adenovirus, log10 VL at CMX001 initiation, median (range)
ALC at CMX001 initiation, median (range)
ALC <300 at CMX001 initiation, n (%)
Response to treatment
Total CMX001 exposure, days, median (range)
Adenovirus, log10 VL after 4 weeks of CMX001, median (range)Drug Safety
Five patients (38.46%) were receiving renal
replacement therapy at the time of CMX001 initiation;
2 of these 5 patients (40%) recovered renal function by
the end of the follow-up period. There was no signifi-
cant change in the median creatinine clearance
between week 0 and week 8 of CMX001 therapy in
the children (68.63 mL/min [range, 10-306 mL/min]
to 92.03 mL/min [range, 10-287.8 mL/min]; P 5 .58)
or the adults (34 mL/min [range, 14-165.15 mL/min]
to 39.22 mL/min [range, 13-122.8 mL/min];
P 5 .38). No patient discontinued therapy before the
end of the study specifically due to CMX001-related
side effects. No other serious adverse events (grade 3
and 4 Common Terminology Criteria for Adverse
Events, version 4.0), including renal, gastrointestinal,
ormarrow toxicity, were attributed toCMX001 during
the treatment phase or follow-up.DISCUSSION
This retrospective study examined initial outcomes
in a cohort of patients receiving salvage CMX001 for
adenoviral disease. All patients were immunocompro-
mised and had failed previous cidofovir therapy. In
these patients, the effects of CMX001 on adenovirus
replication became evident during the first week of
treatment and were sustained throughout the follow-
up period. Nearly two-thirds of patients treated with
CMX001 had a $10-fold drop in VL after just 1 week
of therapy, and up to 70%patients by 2months of treat-
ment. Responders sustained at least a 100-fold drop
from baseline or had an undetectable VL at the end of
the follow-up period.
Infection occurred preferentially in younger
patients in this cohort, corresponding to other studies
showing a higher prevalence in pediatric populations
[1]. Although the timingof adenovirus infections varied,
most infections occurred relatively early after transplan-
tation. This period is associated with the highest degreers
sponders (n 5 9) Nonresponders (n 5 4) P Value
6 (1.42-43) 24.7 (0.92-66) .99
6 (66.66) 2 (50.0) .99
7 (77.78) 3 (75) .99
4 (44.4) 2 (50) .99
105 (17-720) 45 (15-161) .70
34 (7-90) 21 (5-21) .18
4.57 (2.00-8.04) 5.5 (4.14-6.19) .50
5.06 (2.00-7.81) 5.1 (4.33-6.65) .99
300 (7-1500) 200 (90-400) .70
4 (44.4) 2 (50) .99
14 (6-72) 23.5 (15-34.7) .70
2.85 (0-4.77) 5.29 (2.48-6.78) .07
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Figure 3. Overall survival after starting therapy for disseminated ade-
novirus in responders and nonresponders to CMX001 (n5 13). Median
survival was 196 days in the complete responders and 54.5 days in the
nonresponders (P 5 .04).
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consistentwithpreviously reportedepidemiologic stud-
ies of adenovirus in transplantation [4,11,26,37,38].
Delayed recovery of T cell immunity has been
considered a risk factor for posttransplantation adeno-
virus infection; conversely, recovery of T cell immu-
nity has been shown to be essential for the clearance
of adenovirus infection [39-41]. To assess whether
lymphocyte recovery was a confounding factor in the
response to CMX001 treatment, we simultaneously
measured ALC and adenovirus VL at each time
point. The ALC increased significantly in the first 2
weeks after initiation of CMX001, and largely
plateaued thereafter. The change in ALC from
baseline was inversely correlated with VL only at
week 6, and was not believed to significantly
confound this uncontrolled estimation of the
response to CMX001 therapy over the relatively
short follow-up period.
Unlike cidofovir, for which strict monitoring is nec-
essary, with nephrotoxicity seen in up to 50%of patients
and neutropenia in up to 20% [27,42-44], CMX001 was
well tolerated. Although assessing toxicity is difficult in
retrospective studies, especially in high-risk patients
with baseline abnormalities and baseline risk factors
for myelosuppression, attributable toxicities were not
reported during the follow-up period. Consistent with
previously reported data [33], renal function improved
or remained unchanged during CMX001 therapy, sug-
gesting a lack of nephrotoxicity. Although encouraging,
these safety data must be interpreted with caution.
In previous studies, disseminated adenovirus dis-
ease in immunocompromised patients has been associ-
ated with up to 80% mortality [11,26,37,38,45]. Thehigh mortality in our medically complex patient
population was influenced by the presence of other
pathogens, GVHD, and progression of the underlying
disease. Survival was improved in the patients with
VR compared with those who failed to respond to
CMX001. Based on these data, the virologic efficacy
of CMX001 was approximately 70%. These nonrand-
omized results must be interpreted with caution,
Prospective comparative trials are needed to estimate
the true benefit of this drug.
This studywas limitedby its retrospective nature and
the heterogeneity of the study population. We
specifically limited our analysis to patients with virologic
data sufficient for comparative analysis. By selecting
a population that had survived for at least 4 weeks after
starting the drug, we likely biased our population to
one more likely to have a better outcome. It is
important to put this in context, however, particularly
because these patients were extremely high-risk, having
failed primary cidofovir therapy and being burdened
withmultiple comorbidities.Becauseofour small sample
size, statistical effects must be interpreted with caution.
In particular, the survival of our patients might have
been affected by variances in treatment, severity of pri-
mary disease, CMX001 dosage, and underlying disease.
Although this is the largest multicenter study to date
evaluating the effectiveness of this new agent adminis-
tered through theFDAEINDprocess, the small number
of patients, center-specific treatment variations, and dos-
ing differences between patients limit broader conclu-
sions. We also appreciate that, as with any oral drug,
absorption could be a factor affecting response.Unfortu-
nately, differences in drug absorption could not be as-
sessed in this study, because the sampling was not
sufficient to specifically characterize absorptionpatterns.
Finally, although there were no major complications
from therapy, we had a limited ability to examine the po-
tential side effects or drug toxicities associated with
CMX001.CONCLUSIONS
This is the first multicenter cohort to provide
clinical data on the safety and efficacy of CMX001 as
salvage therapy for highly immunocompromised pa-
tients with adenovirus disease. Although the number
of subjects in this cohort was small, the sustained VR
in patients who had failed cidofovir treatment suggests
that CMX001 may be an effective treatment for severe
adenovirus disease. Adenovirus can be a major cause of
morbidity and mortality in immunocompromised
patients, and a safe and effective antiviral agent would
be an important therapeutic advance in the field of
transplantation. Prospective trials of CMX001 as
treatment for adenovirus disease in immunocompro-
mised patients are warranted.
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